Asset profile
JNJ-42756493
Small molecule
Evidence outlook · lead readout
NCT02699606 · Neoplasm
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT02699606: All 35 participants received erdafitinib openly with no control group and no masking, so there is no comparison group to show whether the drug, rather than the disease's own course, drove any response. Results for the primary tumor-response measure have not yet been posted.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.